Trius Therapeutics, which is developing an antibiotic for serious gram-positive Staph infections, raised $50 million by offering 10 million shares at $5 after originally planning to sell 6 million shares at a range of $12-$14. Trius Therapeutics plans to list...read more
Trius Therapeutics, which is developing an antibiotic for serious gram-positive Staph infections, lowered the proposed deal size for its upcoming IPO on Monday. The San Diego, CA-based company now plans to raise $50 million by offering 10 million shares at a...read more
Trius Therapeutics, which is developing an oral antibiotic for serious staph infections, kicked off a new IPO roadshow this week after temporarily postponing its IPO in March to adjust the Phase 3 protocol for its lead drug. The San Diego, CA-based biotech,...read more
Trius Therapeutics, which is developing an oral antibiotic for serious staph infections, announced that it is temporarily postponing its IPO due to plans to conform Phase 3 protocol for the drug (torezolid phosphate) to accomodate new draft guidance recently...read more
Trius Therapeutics slashes IPO price to $5, offers more shares
Trius Therapeutics, which is developing an antibiotic for serious gram-positive Staph infections, raised $50 million by offering 10 million shares at $5 after originally planning to sell 6 million shares at a range of $12-$14. Trius Therapeutics plans to list...read more
Trius Therapeutics decreases proposed IPO deal size
Trius Therapeutics, which is developing an antibiotic for serious gram-positive Staph infections, lowered the proposed deal size for its upcoming IPO on Monday. The San Diego, CA-based company now plans to raise $50 million by offering 10 million shares at a...read more
Biotech Trius Therapeutics back on IPO calendar for week of July 26
Trius Therapeutics, which is developing an oral antibiotic for serious staph infections, kicked off a new IPO roadshow this week after temporarily postponing its IPO in March to adjust the Phase 3 protocol for its lead drug. The San Diego, CA-based biotech,...read more
Trius Therapeutics delays $78 million IPO to conform protocol for Phase 3 trial
Trius Therapeutics, which is developing an oral antibiotic for serious staph infections, announced that it is temporarily postponing its IPO due to plans to conform Phase 3 protocol for the drug (torezolid phosphate) to accomodate new draft guidance recently...read more